New diabetes clinical trial: A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Published on: October 26, 2025 at 11:00PM
Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Drug: Efimosfermin Alfa; Drug: Placebo
Sponsors: GlaxoSmithKline
Not yet recruiting
https://ift.tt/gzJw7i0